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Abstract 
Background: Diabetes is a socioeconomic burden in Pakistan. International diabetes federation reported 6.9 million 
cases of diabetes and 87,548 deaths due to diabetes in Pakistan in 2014. Peroxisome proliferators-activated receptors 
are transcription factors, regulating several physiological processes.
Aim: The aim of the current study was to determine the prevalence of silent variant C1431T in exon 6 of PPAR-y and 
analyze its effect on various anthropometric and biochemical parameters in a Pakistani cohort.
Methods: We collected 926 samples, 500 healthy controls (fasting blood sugar <99 mg/dL, random blood 
sugar <126 mg/dL) and 426 cases with diabetes (fasting blood sugar >99 mg/dL, random blood sugar >126 mg/dL). 
The genotyping was done by polymerase chain reaction restriction fragment length polymorphism (PCR–RFLP) and 
serum biochemical parameters were determined by commercially available kits.
Results: The genotyping results by RLFP showed allelic frequency C = 61.2 % and T = 38.8 % in controls while 
C = 74.5 % and T = 25.5 % in cases (OR 0.536, CI 0.439–0.655, p = 8.2 × 10−10) and genotypic frequency CC = 38.8 %, 
CT = 44.7 %, TT = 16.5 % in controls. While CC = 53.6 %, CT = 41.4 %, TT = 5.1 % in cases (OR 0.544, CI 0.408–0.726, 
p = 2.3 × 10−10). The rare T allele appeared to be a protective allele i.e., the presence of rare allele lowered the risk of 
diabetes in the studied cohort. The biochemical and anthropometric parameters were analyzed for any significant 
association with the SNP showing that C1431T variant has an association with BMI, weight, fasting glucose and LDLC. 
However, no significant association was found with age, gender, height, HDLC, TC, triglycerides and leptin.
Conclusion: In conclusion, the presence of minor allele lowers the risk of diabetes and the effect may involve modu-
lating certain serum parameters.
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Background
Diabetes is a metabolic disorder, associated with a num-
ber of specific and non-specific micro/macrovascular 
complications. It is characterized by hyperglycemia, 
which can either be due to improper functioning of the 
pancreatic β-cells which decreases insulin production, 
or the resistance of body cells to insulin wherein insulin 
production by β-cells is normal but cells cannot respond 
to it [1].
Diabetes is a common cause of premature mortality 
and prolonged illness in Pakistan. It is highly prevalent in 
almost all regions of Pakistan, with an overall prevalence 
of 22.04 % in urban and 17.15 % in rural areas. The gen-
der wise distribution of diabetes in different provinces of 
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Pakhtunkhwa; 11.1  % both sexes, Balochistan; 10.8  % 
both sexes, Sindh; males 16.2 %, females 11.7 % [2].
Peroxisome proliferators-activated receptors (PPARs) 
are transcription factors and members of the super 
family of steroid hormone receptors, activated by lipid 
soluble membrane permeable ligands, regulating the 
expression of several target genes. The physiological pro-
cesses affected include insulin signaling, lipid and glucose 
metabolism and adipogenesis [3]. There are three types 
of PPARs, PPARα, PPARβ and PPARƳ among which var-
iations in PPARƳ gene are mostly implicated in obesity, 
diabetes and many other disorders [4].
PPARγ is located on chromosome 3p25 [5]. The func-
tions of this nuclear transcription factor include regu-
lation of multiple genes involved in energy regulation, 
glucose and lipid metabolism, and plays role in insulin 
sensitivity. A silent variant present in the exon 6 of the 
PPARγ gene involves substitution of cysteine at nucleo-
tide position 1431 with thiamine. It was identified in 1998 
by Meirhaeghe et al. and is also known as His477His. It 
has been shown to be associated with various diseases 
and extensive studies have been carried out to assess the 
effects of this polymorphism on many aspects of human 
physiology [6]. This variant has been investigated in dif-
ferent populations but the association of this variant with 
obesity, diabetes and cardiac disorders as a protective 
SNP remains controversial [7–11]. The aim of the study 
was to check the association pattern of PPARƳ C1431T 
polymorphism with diabetes in the diabetic patients and 
healthy controls of Pakistani origin, and determine its 




A total of 926 samples (426 clinically diagnosed type 2 
diabetic cases and 500 normal controls) were recruited 
from the hospitals and diabetic centers of Punjab, Paki-
stan. Inclusion criteria for diabetic subjects were (i) dia-
betes diagnosed according to etiologic classification of 
diabetes by the International Diabetes Federation (IDF) 
and (ii) confirmation that all the grandparents of the 
subjects are of Pakistani origin. The exclusion criteria 
consisted were the presence of any infectious disease, 
conditions where phlebotomy is contra-indicated, age 
below 10  years, body mass index (BMI)  ≤18.5  kg/m2, 
pregnancy, handicapped/mentally disturbed individuals, 
obese (obesity defined as: BMI >23 kg/m2 as overweight 
and BMI>  26  kg/m2 as obese, criteria used for Asian 
populations as described previously [12]), cancer and 
ethnicity other than Pakistani. The recruitment was done 
between July 2014 and April 2015. The controls were 
healthy subjects from the general population with normal 
blood sugar levels (<126  mg/dL random or  <99  mg/
dL fasting). All the subjects were genetically unrelated 
and gave written informed consent. The procedures 
employed were according to the Helsinki declaration and 
an ethical approval was obtained from the institutional 
ethical board.
Blood sampling
Venous blood was collected from the subjects in the fast-
ing state. Five milliliters blood was collected from the 
median cubital vein using aseptic measures. Half was dis-
pensed in an EDTA vial and used for DNA isolation while 
rest half was poured in a gel clot activator containing vial 
and used for biochemical analysis.
Biochemical parameters’ determination
Gel clot activator containing vial was centrifuged to sepa-
rate plasma for determination of biochemical parame-
ters. Serum was screened for HBV, HCV and HIV. Serum 
fasting plasma glucose (FPG), total cholesterol (TC), tri-
glycerides (TG), high density and low density lipoprotein 
cholesterol (HDL-c, LDL-c), were determined using com-
mercially available kits (Spectrum Diagnostics, Egypt), 
leptin was measured by LDN Nordhorn leptin ELISA kit 
whereas insulin concentration was measured using an 
electrochemiluminescence method as described previ-
ously [13], and HOMA-IR was calculated.
Genotyping
Genomic DNA isolation was done manually by salting 
out method and results were checked on 1  % agarose 
gel. The DNA was quantified by measuring the optical 
density and was standardized to a final concentration of 
10 ng/µl. PCR was done with the following set of primers. 
Forward primer 5′-CCTCCCCACCTATTTAAGATA-3 
and reverse primer 5′-CGGGATCCGTACAAGTC 
CTTGTAGATCTCC-3′. PCR consisted of an initial 
denaturation at 95 °C for 2 min, followed by 35 cycles of 
denaturation at 95 °C for 30 s, annealing at 57 °C for 45 s, 
extension at 72 °C for 45 s and a final extension at 72 °C 
for 10 min. Advanced Primus 96 (PeqLab) thermal cycler 
was used for amplification. 397 bp PCR product was sub-
jected to restriction digestion using restriction enzyme 
BsaA1 at 30  °C for 6  h [14]. It cuts the product in wild 
type state producing fragments of 305 bp and 92 bp. PCR 
and digestion products were analyzed on 2 % agarose gel.
Results
The diabetic cases studied, were from the government 
hospitals, the diabetic centers and laboratories while 
controls were unrelated subjects, but ethnically matched 
and healthy individuals from the general population. 
The general characteristics of the subjects are given in 
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Table  1 and show that, except for height and gender (p 
value 0.314 and 0.108 respectively), all other param-
eters were found to be significantly different between 
cases and controls. The mean age (years) of cases was 
42.12 ±  9.53 and of controls was 49.84 ±  8.46 whereas 
for males, it was 47 ± 12.7 and of females was 46 ± 11.6. 
The proportion of diabetic patients suffering popula-
tion from other disorders, including foot ulcer, car-
diovascular disease, hypocholesteremia, hypertension, 
nephropathy, and retinopathy was higher in the cases 
than the controls (Table  2). The average blood pressure 
of the diabetic patients was normal 120/80  mmHg−1 
however the patients suffering from cardiovascular 
disease and nephropathy showed high blood pressure 
140/80 mmHg−1.
The distribution of observed genotypes is given in 
Table  3. The study population was in Hardy–Wein-
berg equilibrium (p =  0.561). The allelic frequency was 
C = 0.745 and T = 0.255 in diabetic cases and C = 0.612 
and T = 0.388 in the controls (OR 0.536, CI 0.439–0.655, 
p  =  8.2  ×  10−10), whereas genotypic frequency was 
CC = 0.536, CT = 0.414, and TT = 0.051 in cases and 
CC  =  0.388, CT  =  0.447, TT  =  0.165 in controls (OR 
0.544, CI 0.408–0.726, p = 2.3 × 10−10). Logistic regres-
sion was used to analyze the association of C1431T pol-
ymorphism with diabetes. The result showed that the 
polymorphism is significantly associated (p = 0.004) with 
diabetes in the Pakistani study subjects.
The serum was subjected to analysis of certain param-
eters reported to play role in progression to diabetes. 
There was a slight difference between the values of serum 
traits between the males and females. The association of 
variant C1431T with anthropometric traits (gender, age, 
height, weight, BMI) was analyzed by one way ANOVA 
(analysis of variance) and the results were confirmed by 
an independent t-test. The mean and the standard devia-
tion values of the genotype TT were slightly less than 
the CC and CT genotype. The BMI (p = 2.1 × 10−4) and 
weight (p  =  2.2  ×  10−5) were significantly associated 
with the variant, however, age (p  =  0.710) and height 
(p =  0.562) did not show association with C1431T pol-
ymorphism (p  =  0.0761) (Table  4). Among biochemi-
cal parameters, the C1431T was significantly associated 
with the fasting glucose level (p = 2.1 × 10−3) and LDLC 
(p  =  0.041). However, it showed no significant asso-
ciation with triglycerides (p  =  0.862), total cholesterol 
(p  =  0.809), HDLC (p  =  0.775) and leptin (p  =  0.701) 
(Table 5).
Table 1 General characteristics of the study subjects
BMI body mass index, n total number
* Indicates significant differences
Parameters Diabetic (n = 426) Non-diabetic (n = 500) p value
Gender
 Male 228 272 0.108
 Female 198 228 0.108
Age (yr) 47.55 ± 12.3 35.78 ± 13.4 0.0001*
Height (ft) 5.50 ± 0.3 5.49 ± 0.59 0.756
Weight (Kg) 68.6 ± 13.83 65.38 ± 13.7 0.0004*
BMI (Kg/m2) 22.7 ± 5.6 21.67 ± 5.3 0.0043*
Table 2 Prevalence of comorbidities
Disorders Frequency (%)
Cases (n = 426) (%) Controls (n = 500)
Cardiovascular disease 8.1 2 %
Nephropathy 7 0
Retinopathy 3.4 0
Foot ulcer 3.8 0
Hypocholesteremia 7 1 %
Hypertension 8.9 2.3 %















95 % CI p value
C 61.2 74.5 0.536 0.439–0.655 8.2 × 10−10
T 38.8 25.5
CC 38.8 53.5 0.544 0.408–0.726 2.3 × 10−10
CT 44.7 41.4
TT 16.5 5.1
Table 4 Association between  polymorphism of  C1431T 
and anthropometric traits in study population
BMI body mass index
* Indicates significant association
Anthropometric traits Genotype Mean ± SD p value
Age (years) CC 45.91 ± 13.04 0.710
CT 32.15 ± 12.11
TT 47.83 ± 11.21
Weight (Kg) CC 78.20 ± 15.11 2.2 × 10−5*
CT 72.98 ± 13.01
TT 63.54 ± 12.53
Height (ft) CC 5.41 ± 0.42 0.562
CT 5.55 ± 0.26
TT 5.53 ± 0. 29
BMI (Kg/m2) CC 23.94 ± 3.28 2.1 × 10−4*
CT 22.35 ± 5.01
TT 21.11 ± 4.52
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Discussion
The current study analyzed the allele and genotype fre-
quencies of PPARγ gene C1431T polymorphism that is 
well studied in the Caucasians but no report on this variant 
is available for the Pakistani population. We aimed to find 
out its association, if any, with serum biochemical parame-
ters in order to check a possible mechanism of action. This 
polymorphism is widely studied in different populations, 
but the results of its association patterns are controversial. 
Some studies have reported its protective role in diabetes, 
whereas others have found no such effect [15].
The mean weight observed in cases was higher than the 
normal population. In type 2 diabetes, the patient may 
eat more, but still feel hungry and results in overweight, 
whereas in type 1 diabetes patients rapid weight loss is 
observed [16]. In people with type 1 diabetes, insufficient 
insulin prevents the body from getting glucose from the 
blood into the body’s cells to use as energy. When this 
occurs, the body starts burning fat and muscle for energy, 
causing a reduction in overall body weight. Unexpected 
weight loss has often noticed in people prior to a diagno-
sis of type 1 diabetes.
There was a difference observed between the values of 
serum traits between the males and females, which may 
be due to the difference in certain sex-limited hormones, 
which are gender associated and have an influence on the 
body of individual metabolic processes. All the serum 
traits (total cholesterol, leptin, triglyceride, HDLC, LDLC 
and fasting glucose) showed increased values in diabetic 
patients as compared to non-diabetic controls. In previ-
ous studies it has been reported that the decreased insu-
lin action, insulin deficiency and/or insulin resistance in 
tissues is the primary cause of diabetes. The most impor-
tant defect in insulin-deficient subjects appears to be a 
deficiency of lipoprotein lipase, which is responsible for 
the removal of the triglyceride-rich lipoproteins. Cho-
lesterol levels may be elevated and it is important to dis-
tinguish between LDL and HDL as the causes for these 
increases. HDLC level may increase in insulin-dependent 
subjects, whereas it may be decreased in obese non-insu-
lin-dependent patients. Mild elevations of LDLC may 
occur in inadequately controlled type I and II diabetic 
patients [17].
Various studies have been conducted in other popula-
tions including Iranian [18], Mexican-Americans [19], 
African-Americans [20], Asian [21], and Chinese Han 
[22] populations regarding the role of PPARy variant 
C1431T to determine the allele frequency and the gen-
otypic distribution. There have been no studies of the 
distribution of C1431T polymorphism in the Pakistani 
population in context to diabetes previously. The results 
were in accordance with some of the previous reports 
which showed that the polymorphism C1431T was asso-
ciated with lower diabetes risks [23].
A highly showed significant association of C1431T 
polymorphism with BMI and weight was observed in the 
current study indicating a lowering effect of T allele on 
weight and BMI in the study subjects. These results are 
in accordance with a previous study conducted in Chi-
nese and Quebec populations [11, 24]. The presence of 
the homozygous wild type appeared to increase BMI and 
weight, leading to obesity and an increased risk of having 
diabetes. The heterozygous study subjects showed a mod-
erate trend of anthropometric traits. It has been reported 
in the previous studies that C1431T variant is associated 
with a higher BMI in type 2 diabetic patients [25].
Among the biochemical parameters, the only observed 
significant association of the polymorphism was with 
LDLC. The low density lipoprotein cholesterol serum 
concentration (LDL-C) is an independent diabetes and 
CHD risk factor and LDL-C lowering drugs reduce CHD 
risk [26, 27]. The biochemical and genetic basis of eleva-
tion in blood lipids is not fully understood, but their her-
itability has been estimated to be at least 50 % [28].
Single nucleotide polymorphisms (SNPs) can be used 
to examine whether a genetic biomarker is causally linked 
to a disease risk or not [29]. Most of the SNPs in the 
genes regulating blood lipids are inherited independently 
and affect lipid levels quantitatively [30]. In contrast to a 
Table 5 Association between  C1431T polymorphism 
and serum traits
HDLC high density lipoprotein cholesterol; LDLC low density lipoprotein 
cholesterol
*Indicates significant association
Serum traits Genotype Mean ± SD p value
Glucose (mmol/L) CC 7.11 ± 1.60 2.1 × 10−3*
CT 6.20 ± 1.81
TT 5.22 ± 0.91
Triglyceride (mmol/L) CC 2.37 ± 0.86 0.862
CT 2.37 ± 0.82
TT 2.30 ± 0.65
Cholesterol (mmol/L) CC 5.09 ± 0.99 0.809
CT 5.07 ± 1.28
TT 4.97 ± 1.31
LDLC (mmol/L) CC 2.69 ± 0.71 0.041*
CT 2.59 ± 0.65
TT 2.39 ± 0.45
HDLC (mmol/L) CC 1.40 ± 0.45 0.775
CT 1.43 ± 0.47
TT 1.43 ± 0.41
Leptin (mg/dL) CC 3.59 ± 1.46 0.151
CT 3.46 ± 0.74
TT 3.27 ± 1.11
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large body of evidence available in Caucasians, data on 
the genetic regulation of lipids in Pakistani population 
is limited [31]. The allele frequencies of SNPs may show 
interethnic variations due to different linkage disequilib-
rium (LD) patterns, genetic drift, gene flow, mutation or 
admixture. Risk allele frequencies of some SNPs may be 
more prevalent in specific ethnic groups, or their effects 
may be modified due to environment or life style changes 
[32, 33]. This in turn may generate variations in disease 
outcomes across ethnicities [34]. Therefore, studies in 
non-European people will help to evaluate the true rel-
evance of findings in European people [35, 36].
Conclusion
In conclusion, these findings suggest that the presence 
of a polymorphism may not always increase the risk of a 
disease, rather sometimes a SNP may be beneficial, the 
C1431T polymorphism is an example of this. This SNP 
appeared to lower the risk of type 2 diabetes, the allele as 
well as genotype frequencies of minor allele were higher 
in controls as compared to cases. This variant showed 
significant association with weight, BMI and LDL-C indi-
cating a potential role in the development of metabolic 
anomalies like diabetes.
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